Skip to main content

IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

IBA et SCK CEN lancent Pantera

Thursday, September 22, 2022 - 15:03

<p><span><span><span><span><span><strong><span lang="EN-US"><span>Louvain-La-Neuve, Belgium, 22 September 2022</span></span></strong><span lang="EN-US"><span> – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&amp;D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (<sup>225</sup>Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on <sup>225</sup>Ac. </span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><span lang="EN-US"><span>The complementarity of IBA and SCK CEN’s expertise has been demonstrated by the extensive and comprehensive R&amp;D work that has been conducted during the last year as they work towards being able to produce large volumes of <sup>225</sup>Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027.</span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><span lang="EN-US"><span>Sven Van den Berghe, former Director of the Nuclear Materials Science Institute at SCK CEN, has been appointed as Chief Executive Officer, and Samy Bertrand, former technical leader for theranostics applications at IBA, takes the position of Chief Technical Officer.</span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-US"><span>Bruno Scutnaire, President of IBA RadioPharma Solutions and Chairman of the Board of Directors of Pantera, said:</span></span></strong><span lang="EN-US"><span> “<em>Actinium-225 offers great promise for the treatment of a large variety of cancers, but only very little of the material is available worldwide today.&nbsp; Once cancer treatments based on <sup>225</sup>Ac receive approval, Pantera will focus on enabling access to a dependable supply of this promising isotope</em>.” </span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-US"><span>Peter Baeten, Deputy Director-General of SCK CEN and Board member of Pantera, commented</span></span></strong><span lang="EN-US"><span>: <em>“Launching Pantera was a logical choice for SCK CEN and IBA, allowing the joint-venture to leverage the innovative capabilities of both organizations, whilst utilizing the speed of an autonomous startup necessary in this fast-evolving field.” </em></span></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-US"><span>Sven Van den Berghe, appointed Chief Executive Officer of Pantera, added</span></span></strong><span lang="EN-US"><span>: “<em>I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers ’A better fight for life’, potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future</em>.”</span></span></span></span></span></span></span></p> <p>&nbsp;</p> <div> <p><span><span><span><span><span><em><span lang="EN-US"><span>Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer.</span></span></em></span></span></span></span></span></p> </div> <p>&nbsp;</p> Read Full Press Release EN  
Read Full Press Release FR  
Read Full Press Release NL  
Share

More news

-

IBA Business Update – Third Quarter 2022

Louvain-La-Neuve, Belgium, 17 November 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022. &nbsp; Group Overview Business operations continue to be strong, with good performance across all four business units Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million) &nbsp; Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.” &nbsp; Proton Therapy 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1 and 15 Proteus®ONE1 systems in progress An active global pipeline, highlighting the strength of proton therapy market across all geographies A total of 40 service contracts now generating recurring revenues globally IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH®2 Proton Therapy Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL) The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer Other Accelerators (RadioPharma, Industrial) Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron® electron beam accelerators for commercial production of radioisotopes Launched Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab® PLUS in Ghana &nbsp; Dosimetry Signed a strategic alliance for radiation therapy dosimetry solutions with ScandiDos A.B. (SDOS.ST) and made a minority investment in the company IBA’s dosimetry solutions were made compatible with Halcyon® and Ethos™ radiotherapy and adaptive therapy solutions, post-period end Expanded IBA’s myQA® iON technology into Radiation Therapy, post-period end &nbsp; Outlook IBA has continued to perform well across all business units in 2022 to date and this momentum is expected to persist for the remainder of the year and beyond. The pipeline remains highly active in all businesses, underpinning visibility for the period ahead. Whilst some supply chain and inflation related challenges remain, we are seeing gradual improvements and as a business, we continue to mitigate macroeconomic pressures. With an exceptionally strong balance sheet, we are continuing with our extensive investment plan to bolster our infrastructure, supply chain and logistics, reinforce our digital ambitions and continue to maintain our market-leading technology. Alongside this, we will look to seek value-enhancing opportunities to drive future sustainable growth. &nbsp; Financial calendar Full Year Results 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23 March 2023 Business Update First Quarter 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18 May 2023 General Assembly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 June 2023 &nbsp; &nbsp; Proteus®PLUS and Proteus®ONE are brand names of Proteus 235 ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase. &nbsp; &nbsp;
See more
-

IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

New contract to provide broader access to diagnostics in emerging markets &nbsp; Louvain-La-Neuve, Belgium, October 13, 2022 – IBA&nbsp;(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer treatment in West Africa. The contract marks IBA’s increasing presence in the region with operations in 21 countries. &nbsp; IntegraLab® PLUS is a fully integrated solution that combines equipment and services for establishing a radiopharmaceutical GMP production center, tailored to each customer’s specific needs. The contract includes the delivery of an IntegraLab® solution, consisting of the installation and integration of a Cyclone® KIUBE 100 with Synthera® Extension, Synthera®+ HPLC and IFP loader. Sweden Ghana Medical Center will benefit from IBA's expertise for the complete setting-up of its radiopharmacy. &nbsp; This contract follows several others signed in Tanzania and South Africa, and further highlights IBA’s ambition to broaden access to cancer diagnostics and treatments in regions of the world with low population density and limited access to healthcare. The demand for diagnostic and therapeutic equipment in Africa is rapidly growing, with cancer cases rising to over 800 000 cases*&nbsp;per year in Sub-Saharan Africa. &nbsp; This latest announcement follows IBA’s launch of the Cyclone® KEY in January this year, which will provide more widespread global access to diagnostic solutions in oncology, neurology and cardiology as it answers a demand from the African market for a compact radiopharmaceuticals production solution. &nbsp; Olivier Legrain, Chief Executive Officer at IBA, commented:&nbsp;“This contract marks an important milestone for IBA as we expand the use of our technology into emerging markets such as Africa. Continued innovation from our RadioPharma Solutions Business Unit is vital to providing patients with access to much needed diagnostics and treatments, something that is core to IBA’s mission and reinforced by the continued development of our technology. We look forward to working with SGMC and to helping them to achieve their mission of being at the forefront of cancer care in Africa.” &nbsp; Dr. Clement Edusa, CEO and Medical Director at Sweden Ghana Medical Centre, added: “At SGMC, our vision is to provide the best possible cancer care across West Africa. The IntegraLab® will allow us to provide the most innovative diagnostic imaging tests to our patients, with the hope that we can identify disease and therefore start an appropriate course of treatment much quicker. IBA’s technology, not only provides us with a cost efficient and user-friendly cyclotron system but&nbsp;also tailored solutions that meet our specific needs, allowing us to provide the best possible care to our patients.” &nbsp; *https://gco.iarc.fr/today/data/factsheets/populations/971-sub-saharan-africa-hub-fact-sheets.pdf
See more